By using Massive Bio’s AI-driven solutions, UEPM aims to provide more precise and timely trial matches. Credit: raker / Shutterstock.

US-based oncology software company Massive Bio has entered an expanded partnership with Un Ensayo Para Mi (UEPM), a clinical trial search platform, to enhance access to oncology clinical trials in select regions.

The companies will deploy advanced AI technologies across nine Latin American (LATAM) countries, including Mexico, Brazil, Colombia and Argentina, to improve clinical trial availability and patient care.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Massive Bio’s AI technology is designed to optimise the trial enrolment process by streamlining patient matching, thereby reducing the time and effort required.

The partners aim to improve access to trials for cancer patients in LATAM, striving to close the gap between new treatments and the patients who urgently require them.

Massive Bio co-founder and CEO Dr Selin Kurnaz said: “Expanding our collaboration with UEPM is a pivotal step in our mission to democratise access to clinical trials globally.

See Also:

“By leveraging UEPM’s extensive network and our AI technology, we can ensure that more patients in LATAM have access to cutting-edge therapies.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

UEPM’s comprehensive platform enables patients and healthcare providers to locate trials tailored to specific medical conditions and treatment requirements.

Through the use of Massive Bio’s AI-driven solutions, UEPM aims to provide more precise and timely clinical trial matches to boost participation rates and aid cancer research.

Un Ensayo Para Mi CEO and founder Dr Georgina Sposetti said: “We are thrilled to partner with Massive Bio to bring advanced oncology clinical trial matching to our region.

“This collaboration will significantly improve the accessibility and efficiency of finding suitable clinical trials for our cancer patients, ultimately enhancing their treatment outcomes and quality of life.”

Founded in 2015, Massive Bio operates across 12 countries and employs almost 100 people.

As the first Spanish clinical trial search platform, Un Ensayo Para Mi aims to connect doctors, patients and researchers to enable access to approved clinical trials in Latin America.